SCHEMBL931571

SCHEMBL931571

CCCCCCCCCCCCN[C@@H](CS)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOD1 Q9Y239 2/20 0.49
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
KDM4E B2RXH2 1/20 0.46
THRB P10828 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
PTGS2 P35354 1/20 0.46
THPO P40225 1/20 0.46
RECQL P46063 1/20 0.46
BLM P54132 1/20 0.46
EPHX1 P07099 6/20 0.44
ACE P12821 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
GPR84 Q9NQS5 3/20 0.41
FFAR1 O14842 1/20 0.41
PLA2G2A P14555 2/20 0.41
PLA2G5 P39877 2/20 0.41
CASP2 P42575 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201072 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL252667 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL931570 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL252666 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL8612865 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL25211227 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL21243388 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL21291888 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL20553468 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB
SCHEMBL5801833 1.00 NOD1 (0.49) NOD1MAPTSMN1; SMN2KDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11613565-B2 Isolated peptides derived from the B7 ligand dimer interface and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2023-03-28 US claimed
US-20200276262-A1 PEPTIDES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2020-09-03 US claimed
EP-3691672-A1 PEPTIDES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS Yissum Research Development Company of the Hebrew University of Jerusalem Ltd (IL) 2020-08-12 EP claimed
US-20200148741-A1 ISOLATED PEPTIDES DERlVED FROM THE B7 LlGAND DlMER INTERFACE AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2020-05-14 US claimed
US-10584157-B2 Isolated peptides derived from the B7 ligand dimer interface and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2020-03-10 US claimed
EP-3077415-B1 REDUCTION OF INFLAMMATORY DISEASE SYMPTOMS BY SHORT PEPTIDES THAT INHIBIT SIGNALING THROUGH CD28 YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) 2020-02-12 EP claimed
US-10280209-B2 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 ATOX BIO LTD. (IL) 2019-05-07 US claimed
WO-2019069307-A1 PEPTIDES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-04-11 WO claimed
US-9963497-B2 Reduction of inflammatory disease symptoms by short peptides that inhibit signaling through CD28 YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2018-05-08 US claimed
US-20180044400-A1 ISOLATED PEPTIDES DERlVED FROM THE B7 LlGAND DlMER INTERFACE AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2018-02-15 US claimed
EP-1613651-B1 METHODS AND COMPOSITIONS FOR THE INHIBITION OF MODULATION OF T CELL COSTIMULATORY PATHWAY BY A PATHOGENIC AGENT YISSUM RES DEV CO (IL) 2015-01-07 EP claimed
US-7189398-B2 Broad spectrum pyrogenic exotoxins antagonists and vaccines YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2007-03-13 US claimed
US-7060277-B2 Broad spectrum antagonists and vaccines directed against pyrogenic exotoxins YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-06-13 US claimed
US-20020028211-A1 BROAD SPECTRUM PYROGENIC EXOTOXINS ANTAGONISTS AND VACCINES BAKER BOTTS LLP 2002-03-07 US claimed
EP-0952985-A1 BROAD SPECTRUM PYROGENIC EXOTOXINS ANTAGONISTS AND VACCINES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1999-11-03 EP claimed
US-5961970-A OIL-IN-WATER SUBMICRON EMULSION CONTAINING A PHOSPHOLIPID AS AN EMULSIFIER, A NONIONIC SURFACTANT, AN IMMUNOGEN, AND AN AQUEOUS CONTINUOUS PHASE; FREE OF ADDED MURAMYL PEPTIDES PHARMOS CORPORATION (US) 1999-10-05 US claimed
WO-1998029444-A1 BROAD SPECTRUM PYROGENIC EXOTOXINS ANTAGONISTS AND VACCINES YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1998-07-09 WO claimed
US-5716637-A LIPID CORE WHICH IS SOLID OR LIQUID CRYSTALLINE PHASE AT 25 DEGREE CENTIGRADE AND WHICH IS SURROUNDED BY ATLEAST ONE PHOSOPHOLIPID BILAYER AND ENCAPSULATING A PORTION OF AQUEOUS CONTINUOUS PHASE, IMMUNOGENS ARE ENTRAPPED BY LIPID PARTICLES PHARMOS CORPORATION (US) 1998-02-10 US claimed
WO-1995011700-A1 SUBMICRON EMULSIONS AS VACCINE ADJUVANTS PHARMOS CORP. (US) 1995-05-04 WO claimed
WO-1994026255-A1 SOLID FAT NANOEMULSIONS AS VACCINE DELIVERY VEHICLES PHARMOS CORPORATION (US) 1994-11-24 WO claimed